Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 762

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 762
---
 a result of the Merger, shall instead be issued pre -fundedwarrants exercisable for a number of common shares in excess of the beneficial ownership limitation, at an exercise price equal to the par value of the common shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001per share. In addition, on May 5, 2025, the Merger Agreement was further amended to further extend the outside date to June 30, 2025. On March 27, 2025, the Company entered into a securities purchase agreement, or the March 2025 SPA, with three accredited investors. Pursuant to the terms of the March 2025 SPA, the Company agreed to issue and sell to the investors, in a private placement offering, or the March 2025 Offering, 1,212,122Preferred Shares with a conversion price of $ 1.65per share, for aggregate gross proceeds of $ 2million. Pursuant to the terms of the March 2025 SPA, the investors may purchase up to $ 1million of additional Preferred Shares on identical terms as the initial closing, subject to the Company obtaining shareholder approval. The March 2025 Offering closed on March 28, 2025. The initial closing of the March 2025 Offering resulted in gross proceeds to the Company of to $ 2million. The Company intends to use the net proceeds from the March 2025 Offering for working capital and general corporate purposes, including for expenses relating to the Merger. Further, on March 31, 2025, the Company entered into a Common Shares Purchase Agreement with Alpha Capital Anstalt, or the Facility SPA, relating to a committed equity facility. Pursuant to the Facility SPA, the Company has the right from time to time at its option to sell to Alpha up to $ 25.0million of Company Common Shares, subject to certain conditions and limitations set forth in the Facility SPA. The purchase price of the Company Common Shares that the Company elects to sell to Alpha pursuant to the Facility SPA will be 95% of the volume weighted average price of the Company Common Shares during the applicable purchase date on which the Company has timely delivered written notice to Alpha directing it to purchase Company Common Shares under the Facility SPA. In connection with the execution of the Facility SPA, the Company agreed to issue a pre -fundedwarrant, or the Pre -FundedWarrant, to purchase $